Comments*

 
  • Biochemical Pharmacology Discussion Group

    The Biochemical Pharmacology Discussion Group represents a diverse group of scientists from pharmaceutical and biotechnology companies and university and medical research centers interested in biochemistry, molecular biology, biomedical research, and related areas. The group brings together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development. The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Chapter.

  • Upcoming Events

    Tuesday, October 24, 2017 | 9:00 AM - 5:00 PM

    Towards Transformative Therapies for Sickle Cell Disease

    Speakers: Philip D. Gregory (bluebirdbio), Josh Lehrer (Global Blood Therapeutics), Deepa Manwani (The Children's Hospital at Montefiore, Albert Einstein College Of Medicine), Debra Pittman (Pfizer), Andreas Reik (Sangamo BioSciences), Vijay G. Sankaran (Boston Children's Hospital, Harvard Medical School), Wally Smith (Virginia Commonwealth University Medical Center)

    This symposium will explore recent developments in the field including elucidation of biological mechanisms of disease and cutting-edge clinical science, while underscoring the importance of the patient experience.

    Thursday, November 2, 2017 | 9:00 AM - 5:00 PM

    Mitochondria in Health and Disease

    Speakers: Marcia Haigis (Harvard Medical School), Vamsi Mootha (Harvard Medical School), Andrew Dillin (UC Berkeley), Adam Hughes (University of Utah School of Medicine), Jahar Bhattacharya (Columbia University Irving Medical Center), Jodi Nunnari (University of California, Davis), Navdeep S. Chandel (Northwestern University), J. Wade Harper (Harvard Medical School), and David J. Glass (Novartis Institutes for Biomedical Research)

    This symposium will bring together cross-disciplinary researchers to explore mitochondrial biology, the role played by mitochondria in disease, and their potential as a therapeutic target.

    Tuesday, November 14, 2017 | 9:00 AM - 5:00 PM

    Antibody-Drug Conjugates: Oncology and Beyond

    Speakers: Philip E. Brandish (Merck & Co), Ryan Fleming (MedImmune), Rakesh K. Jain (Harvard University), Greg Thurber (University of Michigan), and Laura Saunders (AbbVie)

    As the development of antibody-drug conjugates moves beyond cancer into other disease indications, this symposium will cover cutting-edge research exploring the challenges and opportunities that exist for the field.

  • Past Events

    Tuesday, April 25, 2017 | 9:00 AM - 5:00 PM

    Complement Pathways in Disease

    Keynote Speaker: V. Michael Holers (University of Colorado School of Medicine)

    The complement system is the first line of defense against infection, however we have yet to capitalize on its therapeutic potential. This symposium will focus on novel insights into the complement pathway in a number of clinical disorders.

    Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM

    Gene Therapy for Rare Diseases

    Speakers: Brian Kaspar (AveXis Inc.), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida Powell Gene Therapy Center), Maria Escolar (University of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and Steven J. Gray (University of North Carolina at Chapel Hill)

    Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in the field, and identify ongoing obstacles on the path to wider use of this approach.

    Tuesday, December 6, 2016 | 9:00 AM - 5:00 PM

    Alzheimer's Disease as a Neurovascular Inflammatory Disorder

    Speakers: Katerina Akassoglou (University of California, San Francisco), Robert Dempsey (University of Wisconsin), Paula Grammas (University of Rhode Island), Steven Greenberg (Massachusetts General Hospital and Harvard Medical School), Jaime Grutzendler (Yale University), Costantino Iadecola (Weill Cornell Medicine), Jeffrey Iliff (Oregon Health & Science University), Berislav Zlokovic (Keck School of Medicine of USC), Heather Snyder (Alzheimer's Association), Zorina Galis (NIH)

    This symposium will highlight basic research and clinical science elucidating the mechanisms underlying the contribution of inflammatory pathways to vascular cognitive impairment and dementia (VCID).

    Tuesday, November 15, 2016 | 9:00 AM - 4:30 PM

    Mucosal Healing of the Intestinal Epithelial Barrier

    Speakers: Thaddeus Stappenbeck (Washington University School of Medicine), Declan F. McCole (University of California Riverside), Jerrold R. Turner (Brigham and Women's Hospital), Linda G. Griffith (MIT), Tim Denning (Georgia State University), and Alan Hanash (Memorial Sloan Kettering Cancer Center)

    This symposium will evaluate emerging research investigating the benefits of achieving mucosal healing in the treatment of intestinal disorders.

    Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM

    Emerging Paradigms in Drug Discovery & Chemical Biology

    Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)

    Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.

    Thursday, September 8, 2016 | 9:00 AM - 5:00 PM

    Targeting Inflammation and Podocytopathy in Chronic Kidney Disease

    Speakers: Hans-Joachim Anders (University of Munich), John Cijiang He (Icahn School of Medicine at Mount Sinai), Matthias Kretzler (University of Michigan), Kevin V. Lemley (University of Southern California), Jochen Reiser (Rush University Medical Center), Myung K. Shin (Merck & Co. Inc.), Katalin Susztak (University of Pennsylvania), and Roger C. Wiggins (University of Michigan)

    Accumulating evidence supports a role for renal inflammation and podocytopathy in pathogenesis and progression of chronic kidney disease. This symposium will delve into the mechanisms underlying this pathology.

    Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM

    MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications

    Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
    Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)

    miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.

    Thursday, April 28, 2016 | 9:00 AM - 5:00 PM

    Epigenetics: Cancer and Beyond

    Keynote Speaker: Craig B. Thompson (Memorial Sloan Kettering Cancer Center)
    Speakers: Michael Elowitz (California Institute of Technology), Eric Campeau (Zenith Epigenetics), Ewelina Kulikowski (Resverlogix Corp), Keiko Ozato (National Institute of Child Health and Human Development), Roberto Pili (Indiana University School of Medicine), Patrick Trojer (Constellation), Christopher Vakoc (Cold Spring Harbor Laboratory), Daniel Vitt (4SC AG)

    Epigenetic abnormalities are a recognized contributing factor in tumorigenesis and other diseases. This symposium describes recent progress in validating the therapeutic potential of small molecule inhibitors targeting epigenetics marks.

    Tuesday, April 26, 2016 | 9:00 AM - 5:00 PM

    Solute Carrier Proteins: Unlocking the Gene-Family for Effective Therapies

    Speakers: Dax Fu (Johns Hopkins School of Medicine), Kathleen M. Giacomini (University of California, San Francisco), Matthias A. Hediger (University of Bern), Avner Schlessinger (Icahn School of Medicine at Mount Sinai), Giulio Superti-Furga (Austrian Academy of Sciences), Ming Zhou (Baylor College of Medicine), and Kim Huard (Pfizer Inc.)

    Solute Carrier Proteins are an untapped resource for drug discovery. This event will discuss breakthroughs in structural biology, cell engineering and metabolomics that hold the promise of "unlocking" this gene family.

    Tuesday, March 22, 2016 | 12:00 PM - 4:00 PM

    Neuronal Connectivity in Brain Function and Disease: Novel Mechanisms and Therapeutic Targets

    Speakers: Wenbiao Gan (NYU Langone Medical Center), Bruce McEwen (Rockefeller University), Eric Nestler (Icahn School of Medicine at Mount Sinai), Amy Robinson (MIT), Bernardo Sabatini (Harvard Medical School), David Sulzer (Columbia University Medical Center)

    Mapping neuronal circuitry provides important insight into mammalian health and disease. This symposium will discuss emerging tools and novel findings that address this important goal.

    Monday, February 22, 2016 | 9:00 AM - 5:00 PM

    Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic

    Speakers: John F. DiPersio (Washington University School of Medicine), Jonathan D. Glass (Emory University School of Medicine), Edward O. Lanphier (Sangamo BioSciences, Inc.), Jane S. Lebkowski (Asterias Biotherapeutics), Racheli Ofir (Pluristem LTD), Mahendra Rao (Wake Forest University School of Medicine), Thomas Schulz (ViaCyte, Inc.), John D. Sinden (ReNeuron Limited), Katherine Tsokas (Janssen Research & Development)

    Advances in gene editing have driven an explosion of pre-clinical cell-based therapies. This event addresses the need to rethink clinical, regulatory, & manufacturing approaches to accelerate the transition of drugs through the clinic.

    Tuesday, December 8, 2015 | 8:30 AM - 4:45 PM

    GLP-1 Treatment for Diabetes and Beyond

    Speakers: David D'Alessio (Duke University), Richard DiMarchi (Indiana University), Jean-Philippe Fortin (Pfizer Global), Keld Fosgerau (Zealand Pharma A/S), Matthew R. Hayes (Perelman School of Medicine, University of Pennsylvania), George G. Holz (State University of New York), Beat Jucker (GlaxoSmithKline), Dong Seok Kim (National Institute on Aging / Peptron Inc), Lotte Bjerre Knudsen (Novo Nordisk), Patrick M. Sexton (Monash University), Konrad Talbot (Cedars-Sinai Medical Center)

    GLP-1 receptor agonists have improved treatment options in type 2 diabetes, although realizing their promise in other areas remains challenging. This symposium highlights preclinical and clinical breakthroughs and opportunities for drug development.

    Tuesday, October 27, 2015 | 8:00 AM - 5:00 PM

    Phenotypic and Biomarker-Based Drug Discovery

    Speakers: Andras J. Bauer (Boehringer Ingelheim USA), Myles Fennell (Memorial Sloan-Kettering Cancer Center), Michael R. Jackson (Sanford Burnham Prebys Medical Discovery Institute), Jonathan A. Lee (Eli Lilly), Martin Main (AstraZeneca), Friedrich Metzger (F. Hoffmann-La Roche Ltd), Bruce A. Posner (University of Texas, Southwestern Medical Center), Yao Shen (Columbia University), Aravind Subramanian (Broad Institute), Giulio Superti-Furga (Austrian Academy of Sciences), Susanne Swalley (Novartis Institutes for Biomedical Research), Jitao David Zhang (F. Hoffmann-La Roche Ltd.)

    This symposium aims to deepen our understanding of phenotypic drug discovery and to foster the exchange of ideas between industry-based and academic research scientists.

    Tuesday, July 28, 2015 | 8:30 AM - 6:00 PM

    Leveraging Big Data and Predictive Knowledge to Fight Disease

    Speakers: Marc D Chioda (Pfizer Inc), Leonard James (Pfizer Inc), Iya Khalil (GNS Healthcare), Michael Matheny (Vanderbilt University), Jason H. Moore (University of Pennsylvania), Nicholas Tatonetti (Columbia University Medical Center), Craig P. Webb (NuMedii, Inc), Chunhua Weng (Columbia University), Diane Wuest (GNS Healthcare)

    In the era of precision medicine, analyses of large volumes of data are key to developing targeted and effective therapeutics. This symposium explores how big data and predictive knowledge are used to guide drug development and clinical trials.

    Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM

    Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development

    Speakers: Richard Allen (Pfizer, Inc.), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Sian Ratcliffe (Pfizer Inc), Matthew Rizk (Merck & Co, Inc), Tim Rolph (Pfizer, Inc.), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)

    Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.

    Monday, April 27, 2015 | 8:30 AM - 4:45 PM

    Non-Motor Symptoms: Unraveling the "Invisible" Face of Parkinson’s Disease

    Speakers: Erwan Bezard (University of Bordeaux), Patrik Brundin (Van Andel Institute), Marie-Francoise Chesselet (UCLA), Diane G. Cook (Parkinson's Disease Foundation), Maurizio Facheris (The Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (University of Toulouse), Anna Sauerbier (NPF International Centre of Excellence, Kings College London), Daniel Weintraub (University of Pennsylvania)

    This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.

    Tuesday, April 7, 2015 | 8:30 AM - 5:00 PM

    Cytokine-Based Immunotherapies

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
    Speakers: Renier J. Brentjens (Memorial Sloan Kettering Cancer Center), Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

    Tuesday, March 24, 2015 | 11:45 AM - 4:00 PM

    Positive Allosteric Modulators for Challenging GPCRs: Identification and Optimization

    Speakers: P. Jeffrey Conn (Vanderbilt University), Ron Dror (Stanford University), Christopher Fotsch (Amgen), Corey Hopkins (Vanderbilt University), Whitney Nolte (Pfizer)

    In this symposium, academic and industry scientists will describe the identification, characterization, and development of PAMs for challenging GPCRs.

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: Chad Cowan (Harvard University), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

  • Steering Committee

    Lynn M. Abell, PhD

    Bristol-Myers Squibb

    Magdalena Alonso-Galicia, PhD

    Bayer Healthcare

    Ildiko Antal, PhD

    Janssen Research and Development
    Cochair

    Joshua Apgar, PhD

    Applied BioMath

    Mercedes Beyna, MS

    Biogen

    Ruth Duffy, PhD

    Otsuka America Pharmaceutical, Inc.

    Thomas Franke, MD, PhD

    NYU Langone Medical Center

    Steven Gross, PhD

    Weill Cornell Medical College
    Cochair

    John Hambor, PhD

    Boehringer Ingelheim

    Julia Heinrich, PhD

    Bristol-Myers Squibb
    Secretary

    Kenneth Jones, PhD

    Allergan

    Katalin Kauser, MD, PhD, DSc

    Global Blood Therapeutics

    Scott MacDonnell, PhD

    Regeneron Pharmaceuticals, Inc.

    Charles Lunn, PhD

    Prolong Pharmaceuticals

    Robert Martone

    St. Jude Children's Research Hospital

    Marco Prunotto, PhD

    Hoffmann-La Roche

    JoAnne Saye, PhD

    AstraZeneca Pharmaceuticals LP

    Roland Staal, PhD

    New Jersey Economic Development Authority

    Claire M. Steppan, PhD

    Pfizer Worldwide R&D

    W. Ross Tracey, PhD

    Novartis Institutes for BioMedical Research

    Erick R. R. Young, PhD

    Boehringer Ingelheim

    George Zavoico, PhD

    JonesTrading Institutional Services LLC


  • Sponsors

    The Biochemical Pharmacology Discussion Group is proudly supported by:

    • Boehringer Ingelheim
    • Regeneron

    ACS New York Section


    Premiere Supporter

    • Pfizer

    Get more information about how you can sponsor a discussion group.

    EmailPrint